Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy

We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) patients responding to third- or later-line therapy (phase A, N = 10) or high-risk patients responding to first-line therapy (pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Garfall, Alfred L., Cohen, Adam D., Susanibar-Adaniya, Sandra P., Hwang, Wei-Ting, Vogl, Dan T., Waxman, Adam J., Lacey, Simon F., Gonzalez, Vanessa E., Fraietta, Joseph A., Gupta, Minnal, Kulikovskaya, Irina, Tian, Lifeng, Chen, Fang, Koterba, Natalka, Bartoszek, Robert L., Patchin, Margaret, Xu, Rong, Plesa, Gabriela, Siegel, Don L., Brennan, Andrea, Nelson, Anne Marie, Ferthio, Regina, Cosey, Angela, Shea, Kim-Marie, Leskowitz, Rachel, Four, Megan, Wilson, Wesley V., Miao, Fei, Lancaster, Eric, Carreno, Beatriz M., Linette, Gerald P., Hexner, Elizabeth O., Young, Regina M., Bu, Dexiu, Mansfield, Keith G., Brogdon, Jennifer L., June, Carl H., Milone, Michael C., Stadtmauer, Edward A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Briefs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975770/
https://www.ncbi.nlm.nih.gov/pubmed/36413381
http://dx.doi.org/10.1158/2643-3230.BCD-22-0074

Ejemplares similares

Ejemplares similares